Market Overview
The global genetic testing market was valued at USD 19.5 Billion in 2024 and is projected to reach USD 44.88 Billion by 2033, growing at a CAGR of 9.70% during the forecast period from 2025 to 2033. Growth is driven by rising prevalence of genetic disorders, technological advancements in genetic testing, and increasing demand for personalized medicine and early diagnosis. North America dominates the market, accounting for over 45.6% share in 2024.
Study Assumption Years
- Base Year: 2024
- Historical Years: 2019-2024
- Forecast Period: 2025-2033
Genetic Testing Market Key Takeaways
- Current Market Size: USD 19.5 Billion (2024)
- CAGR: 9.70% (2025-2033)
- Forecast Period: 2025-2033
- North America dominates with a market share exceeding 45.6% in 2024, driven by technological advances, personalized medicine demand, and government support.
- Increasing incidence of genetic disorders like cystic fibrosis, sickle cell anemia, and Huntington’s disease drives test demand.
- The US genetic testing market is forecast to reach USD 14.4 billion by 2033, propelled by precision medicine and insurance coverage expansion.
- Molecular testing leads the technology segment with 45.2% market share in 2024, benefiting from its precision and wide application.
- Genetic disease diagnosis holds 40.5% market share in 2024, highlighting its critical role in early detection and treatment.
Sample Request Link:
https://www.imarcgroup.com/genetic-testing-market/requestsample
Market Growth Factors
Advancements in genetic testing technologies have significantly propelled the market growth. Enhanced sequencing techniques like next-generation sequencing (NGS) offer detailed genetic disorder insights for early detection and personalized treatments. For instance, cfDNA testing in a study of 1914 women reduced false positives for trisomies 21 and 18, achieving 100% success in detecting aneuploidies. Simplified processes have further led to increased genetic testing adoption across healthcare settings.
Increasing awareness and demand for personalized medicine are shaping market outlook. Personalized medicine uses genetic data to tailor treatment regimes, especially in cancer and reproductive health. A survey with 83% minimal inquiries on direct-to-consumer testing showed over 50% support for genetic counselors and clinical settings. Moreover, 70% respondents considered genetic testing for patients facing privacy or access concerns, reflecting growing interest in genetic predisposition insights.
The rising prevalence of genetic disorders and chronic diseases globally also fuels market growth. Conditions such as sickle cell anemia, cystic fibrosis, Huntington’s disease, cancer, cardiovascular diseases, and diabetes require early genetic diagnosis. WHO reports non-communicable diseases account for 73% of global deaths annually. Early detection improves outcomes and drives demand. In developed countries, the US especially, the volume of genetic testing is growing notably, including prenatal testing for fetal health insight.
Market Segmentation
By Type:
- Predictive and Presymptomatic Testing
- Carrier Testing
- Prenatal and Newborn Testing
- Diagnostic Testing: Used to confirm inherited diseases in symptomatic individuals. It has expanded due to its role in precise diagnosis needed for appropriate treatment across rare genetic and common conditions. For example, hereditary cancer genetic diagnostic testing among medical professionals rose from 19.8% in 2014 to 38.4% in 2018.
- Pharmacogenomic Testing
- Others
By Technology:
- Cytogenetic Testing and Chromosome Analysis
- Biochemical Testing
- Molecular Testing: Includes DNA sequencing and others, leading the market with 45.2% share in 2024. Covers PCR, NGS, and related DNA analysis, widely used for detecting disease-causing genetic changes, cancer genetics for targeted therapies, and genetic predisposition exploration.
- DNA Sequencing
- Others
By Application:
- Cancer Diagnosis
- Genetic Disease Diagnosis: Leading segment with 40.5% market share in 2024. It enables early detection and management of hereditary diseases with single or multiple genetic factors, crucial for treatment and family planning.
- Cardiovascular Disease Diagnosis
- Others
Regional Insights
North America dominates the genetic testing market, holding a 45.6% share in 2024. This leadership is driven by advanced healthcare infrastructure, high healthcare expenditure, top companies and research institutions, strong private investments in personalized medicine, and supportive government policies. The region benefits from growing patient populations with genetic and chronic diseases and increasing public access to genetic testing through both clinical and direct-to-consumer offerings.
Recent Developments & News
- March 2024: Nucleus Genomics introduced a whole-genome sequencing test providing comprehensive insights into an individual's genetic makeup for tailored healthcare.
- February 2024: Sysmex Corporation and Hitachi High-Tech Corporation formed a joint venture to develop advanced genetic testing systems using capillary electrophoresis sequencers, aiming to improve testing accessibility in emerging markets.
Key Players
- 23andme Inc.
- Ambry Genetics Corporation (Konica Minolta Healthcare Americas Inc.)
- Bio-RAD Laboratories Inc.
- Cepheid (Danaher Corporation)
- Eurofins Scientific
- Illumina Inc.
- Invitae Corporation
- Luminex Corporation (DiaSorin)
- Myriad Genetics Inc.
- QIAGEN
- Quest Diagnostics
- Thermo Fisher Scientific
Customization Note
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
Request For Customization:
https://www.imarcgroup.com/request?type=report&id=5788&flag=E
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302
Comments (0)